Physician profile
Charles A Walker
NPI 1154389369
$1,525.86
in general payments reported to CMS, 2019-2025
27 companies · $344 in 2025
The $344 reported for 2025 was more than what a typical Surgery provider received nationally (typical 2025 total: $281).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $108 · 2020: $97.74 · 2021: $280 · 2022: $296 · 2023: $168 · 2024: $232 · 2025: $344.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $717 · Entertainment: $27.11.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $717.22 |
| Entertainment | $27.11 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Organogenesis INC. | $271.23 | 2019-2025 | Puraply, Apligraf, Puraply Am |
| Abbvie INC. | $239.91 | 2021-2025 | Dalvance |
| Misonix INC | $124.39 | 2021 | |
| Elucent Medical | $122.23 | 2022 | |
| Olympus America INC. | $87.60 | 2019-2025 | Visera Elite Video System Center |
| Novo Nordisk INC | $74.88 | 2021-2024 | Wegovy |
| Kerecis Limited | $73.88 | 2025 | Kerecis Surgiclose, Kerecis Graftguide |
| Integra Lifesciences Corporation | $65.05 | 2020 | |
| Astrazeneca Pharmaceuticals LP | $50.42 | 2024-2025 | Farxiga, Airsupra |
| Kci USA, INC. | $36.13 | 2019-2023 | Prevena, V.A.C.Instill |
| Corcept Therapeutics | $36.04 | 2025 | Korlym |
| Allergan, INC. | $32.69 | 2020 | |
| Avanir Pharmaceuticals, INC. | $31.97 | 2021-2022 | |
| Lilly USA, LLC | $31.86 | 2021-2023 | Mounjaro |
| Exact Sciences Corporation | $31.29 | 2025 | Cologuard Collection Kit |
Show all 27 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Optos, INC. | $27.11 | 2025 | Oct Ophthalmoscope, Panoramic Ophthalmoscope, Nfc-700 |
| Janssen Pharmaceuticals, INC | $25.51 | 2021-2022 | |
| Smith+Nephew, INC. | $20.82 | 2023 | Regranex, Collagenase Santyl |
| Boehringer Ingelheim Pharmaceuticals, INC. | $20.20 | 2024 | Jardiance |
| Solventum Corporation | $19.90 | 2025 | Activ.A.C. |
| Ardelyx, INC. | $18.19 | 2024 | Ibsrela |
| Paratek Pharmaceuticals, INC. | $18.02 | 2024 | Nuzyra |
| Reapplix INC. | $16.32 | 2024 | 3c Patch Kit - Box |
| Ethicon US, LLC | $16.19 | 2024 | Megadyne, Vistaseal, Ethicon |
| Mimedx Group, INC. | $15.46 | 2024 | |
| Bioventus LLC | $12.38 | 2022 | |
| Phathom Pharmaceuticals, INC. | $6.19 | 2025 | Voquezna |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Charles Walker listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.